Nabi Biopharmace (NABI)
To see the headquarters in Google Street View &trade, drag this yellow guy: 
over to the red pointer: 
Contact Information:
| Business Address: | - |
| Mailing Address: | 12270 WILKINS AVENUE ROCKVILLE MD 20852 Business Address 12270 WILKINS AVENUE ROCKVILLE MD 20852 301-770-3099 NABI BIOPHARMACEUTICALS CIK #: 000007 |
| Phone: | 301-770-3099 |
| Fax: | 301-770-3097 |
| Website: | http://www.nabi.com |
Company Details:
| Symbol: | NABI |
| SIC: | - |
| State location: | MD |
| Sector: | - |
| State of Inc: | DE |
| Employees: | 42 |
| Type: | NASDAQ |
Key executives:
| Name | Age | Position |
|---|---|---|
| Constantine Alexander | - | Sec. |
| Jordan I. Siegel | 46 | Chief Financial Officer, Chief Accounting Officer, Sr. VP of Fin. and Treasurer |
| Leslie Hudson Ph.D. | 65 | Chief Exec. Officer, Pres, Director, Member of Nominating & Governance Committee and Member of Compensation Committee |
| Raafat Fahim Ph.D. | 58 | Sr. VP of Research, Technical and Production Operations |
| Richard G. Clark | 68 | Chief Admin. Officer and Sr. VP of Admin. |
2nd week November: Portfolio Maintenance Nov 10, 2011, 14:46
Sell Nabi BioPharma (NABI) 10 November 2011; market open (The previous issue was broadcast on 11/4/11)
Preemptive Profit-Positioning: Nabi BioPharma (NABI: Nasdaq): $1.93 X $1.95
Shares of Nabi BioPharma (NABI) have been unable to recover from the disappointing results it received from a key Phase III clinical trial for its smoking-cessation treatment NicVAX in July. A second clinical trial recently completed on the drug read more
| Promoter: Contrarian Press | Paying Party: UNKNOWN | Max Profit: 6.42 % | Gain at close: 2.14 % |
| Stock: NABI | Compensation: Unknown compensation | Avg $ Volume for Period: UNKNOWN | |
| Post # | Subject | Re | Name | Date |
|---|---|---|---|---|
| 1 | How do you do? Is anyone in here? Do you... | 0 | Keon | July 20, 2008, 02:05AM |
| 2 | Here on this message board we are inviting... | 0 | Guest | July 20, 2008, 02:05AM |